Trials / Completed
CompletedNCT01185964
A Study of Olaratumab in Soft Tissue Sarcoma
A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Olaratumab | Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle |
| DRUG | doxorubicin | Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2014-08-01
- Completion
- 2016-04-01
- First posted
- 2010-08-20
- Last updated
- 2017-04-14
- Results posted
- 2017-04-14
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01185964. Inclusion in this directory is not an endorsement.